Pfizer reported better-than-expected Q3 results, driven by strong growth in non-COVID products that offset declines in COVID-19 revenues. The company raised its guidance for 2026, reflecting confidence in its robust drug pipeline and strategic acquisitions. Aggressive cost-saving measures and portfolio diversification position Pfizer well for performance after patent expirations (LOE). Current market valuation is conservative, suggesting potential upside if Pfizer successfully integrates its acquisitions.
Pfizer shares trade at USD 30.95 on Pluang as of Nov 05, 2026 17:11 WIB, showing a modest 0.52% gain for the day. The stock's dividend yield stands at 5.73%, attracting income-focused investors. Despite a 64% sell order activity, Pfizer maintains a strong market cap of $170.99 billion, reflecting steady investor interest amid its portfolio transformation.
Medicus Pharma announced a conference call on November 9, 2026, to review its Q3 financial results and business updates. Key topics include the new co-development and licensing agreement with Pfizer for the CD228V cancer therapy, a proposed business ...
Pfizer reported Q3 2026 revenue of $16.58 billion and adjusted EPS of $0.87, surpassing analyst expectations. The company's non-COVID product portfolio grew 7% operationally, with new and acquired products up 32%, offsetting declines in COVID-related...
Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as CO...
UPS paid $5.4 billion in dividends in 2025, surpassing its free cash flow of $4.8 billion, signaling potential payout risks. Similar concerns apply to Pfizer, AGNC Investment, and Kraft Heinz, where dividends outpace earnings or cash flow, threatenin...
Pfizer reported third-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of 87 cents versus the expected 73 cents, and revenue of $16.58 billion beating the $15.87 billion forecast. The company raised its full-year ...
